NIDA CTN Protocol 0068: Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder
Phase of Trial: Phase III
Latest Information Update: 16 Aug 2019
Price : $35 *
At a glance
- Drugs Bupropion (Primary) ; Naltrexone (Primary)
- Indications Substance-related disorders
- Focus Therapeutic Use
- Acronyms ADAPT-2
- 12 Aug 2019 Status changed from active, no longer recruiting to completed.
- 09 Jul 2019 Planned End Date changed from 1 Jul 2019 to 1 Aug 2019.
- 17 Apr 2019 Status changed from recruiting to active, no longer recruiting.